
|Videos|April 6, 2016
Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer
Author(s)Christina Baik, MD, MPH
Christina Baik, MD, MPH, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer.
Advertisement
Christina Baik, MD, MPH, assistant professor, Seattle Cancer Care Alliance, Thoracic/Head and Neck, Department of Medicine, Division of Medical Oncology, University of Washington, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer. Baik says there was a recent trial comparing the two drugs head-to-head, and results from the trial should be available soon.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































